MAM
DAWN

Martingale Asset Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Martingale Asset Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33,700
Closed -$314K – 812
2025
Q4 		$314K Hold
33,700
– – 0.01% 687
2025
Q3 		$238K Sell
33,700
-1,300
-4% -$8.95K 0.01% 721
2025
Q2 		$228K Sell
35,000
-26,597
-43% -$183K 0.01% 743
2025
Q1 		$488K Sell
61,597
-9,800
-14% -$106K 0.01% 603
2024
Q4 		$905K Buy
71,397
+93
+0.1% +$1.29K 0.02% 496
2024
Q3 		$993K Buy
71,304
+6,219
+10% +$88.7K 0.02% 457
2024
Q2 		$897K Buy
65,085
+11,204
+21% +$164K 0.02% 469
2024
Q1 		$890K Buy
53,881
+20,137
+60% +$301K 0.02% 498
2023
Q4 		$493K Buy
33,744
+3,600
+12% +$43.6K 0.01% 616
2023
Q3 		$370K Buy
30,144
+102
+0.3% +$1.33K 0.01% 652
2023
Q2 		$359K Sell
30,042
-1,900
-6% -$24.8K 0.01% 668
2023
Q1 		$427K Sell
31,942
-100
-0.3% -$1.95K 0.01% 652
2022
Q4 		$690K Buy
+32,042
New +$657K 0.01% 560

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Martingale Asset Management's DAWN Position: Q1 2026 in Review

Martingale Asset Management sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 33,700 shares — an estimated $314K sold.

Martingale Asset Management first reported a position in DAWN in Q4 2022 and held it in 13 quarters. The position peaked at $993K in Q3 2024. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Martingale Asset Management reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Martingale Asset Management sold 33,700 Day One Biopharmaceuticals shares in Q1 2026, an estimated $314K.
  • Martingale Asset Management first reported a position in Day One Biopharmaceuticals in Q4 2022 and held it in 13 quarters.
  • Martingale Asset Management's Day One Biopharmaceuticals position peaked at $993K in Q3 2024.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Martingale Asset Management's 13F filing for Q1 2026, filed 13 May 2026.